[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559964":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":57,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":10,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A- type 2 diabetic patients having sulfonylurease with metformin",null,"Sulfonylurease- gliclazide(30\u002F60\u002F80mg), glimepiride (1\u002F2\u002F3\u002F4mg), glibenclamide (5mg), glipizide (5mg)\n\nmetformin - 500\u002F850\u002F1000mg",[13],"Drug: sulfonylurease with metformin, DPP4 inhibitors with Metformin",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B- type 2 diabetic patients having DPP4 inhibitors with metformin","DPP4 inhibitors- Linagliptin (2.5\u002F5mg), Sitagliptin (50mg), Vildagliptin (50mg)\n\nmetformin - 500\u002F850\u002F1000mg",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","sulfonylurease with metformin, DPP4 inhibitors with Metformin","Oral hypoglycemic agents",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Dr. Sheuly Akter, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+880-1951208001","dr.sheuly7314@gmail.com",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Md Sayedur Rahman, Professor","+880-197184757","srkhasru@bsmmu.edu.bd",[38],{"facility":39,"status":40,"city":41,"state":10,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"BSMMU","RECRUITING","Dhaka","1000","Bangladesh","BD",{"type":46,"coordinates":47},"Point",[48,49],90.40744,23.7104,{"lat":49,"lon":48},[52,56],{"name":53,"role":30,"phone":54,"phoneExt":10,"email":55},"Dr. swapan Kumar Tapadar","88029661064","registrar@bsmmu.edu.bd",{"name":26,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":27,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sheuly Akter","MD resident","100559964","comparative-analysis-of-cost-effectiveness-between-sulfonylureas-and-dpp4-inhibitors-in-combination-with-metformin-in-treatment-of-type-2-diabetic-patients--a-retrospective-observational-study-100559964",false,"NCT06570980","Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","Inclusion Criteria:\n\n* New onset type2 diabetes mellitus diagnosed for 2 -5 years.\n* Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Age 18 years or above.\n* Both male and female.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Unwillingness to participate or unwillingness to give written informed consent.\n* Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.\n* Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Diabetes related complications at the time of diagnosis.","ALL","18 Years",{"count":69,"type":70},200,"ESTIMATED","OBSERVATIONAL","The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.",[74],"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","2024-08-22",{"date":77,"type":78},"2024-08-26","ACTUAL",{"date":80,"type":78},"2023-08-25",{"date":82,"type":70},"2024-08-30",{"name":5,"class":6},1]